Compliance Rate
Compliance Rate
100.0%
Compliant submissions
1
Incompliant submissions
0
Total trials
1
My Organizations' Clinical Trials
Showing 1850 of 3173 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/18/15
End: 04/08/19
Due: 04/08/20
Phase: N/A
Priority: Normal
Start: 11/30/04
End: 04/30/07
Due: 04/30/08
Phase: N/A
Priority: Normal
Start: 01/31/10
End: 03/31/10
Due: 03/31/11
Phase: N/A
Priority: Normal
Start: 12/02/20
End: 03/27/23
Due: 03/27/24
Phase: N/A
Priority: Normal
Start: 09/30/09
End: 08/31/10
Due: 08/31/11
Phase: N/A
Priority: Normal
Start: 08/31/08
End: 07/31/09
Due: 07/31/10
Phase: N/A
Priority: Normal
Start: 11/30/12
End: 06/30/14
Due: 06/30/15
Phase: N/A
Priority: Normal
Start: 06/29/16
End: 10/20/16
Due: 10/20/17
Phase: N/A
Priority: Normal
Start: 07/12/18
End: 11/16/18
Due: 11/16/19
Phase: N/A
Priority: Normal
Start: 05/09/17
End: 06/18/21
Due: 06/18/22
Phase: N/A
Priority: Normal
Start: 11/30/04
End: 09/30/06
Due: 09/30/07
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 02/29/16
Due: 02/28/17
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/22/21
End: 12/07/23
Due: 12/07/24
Phase: N/A
Priority: Normal
Start: 12/15/20
End: 05/13/21
Due: 05/13/22
Phase: N/A
Priority: Normal
Start: 10/31/16
End: 01/31/17
Due: 01/31/18
Phase: N/A
Priority: Normal
Start: 05/31/10
End: 08/31/11
Due: 08/31/12
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Phase: N/A
Priority: Normal
Start: 12/17/19
End: 11/03/20
Due: 11/03/21
Phase: N/A
Priority: Normal
Start: 02/28/10
End: 04/30/10
Due: 04/30/11
Phase: N/A
Priority: Normal
Start: 07/25/24
End: 05/27/27
Due: 05/27/28
Phase: N/A
Priority: Normal
Start: 05/31/09
End: 06/30/09
Due: 06/30/10
Phase: N/A
Priority: Normal
Start: 11/30/13
End: 02/28/15
Due: 02/28/16
Phase: N/A
Priority: Normal
Start: 07/31/14
End: 08/31/14
Due: 08/31/15
Phase: N/A
Priority: Normal
Start: 03/31/99
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/01/17
End: 07/21/17
Due: 07/21/18